PIM3 and hepatoblastoma: In addition, PIM inhibition combined with cisplatin synergistically decreased tumor growth in vivo leading us to believe that PIM3 plays a role in mediating chemoresistance to cisplatin hepatoblastoma by maintaining the SCLCC phenotype.